Glaxo (GSK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Geneos Wealth Management Inc. purchased a new stake in shares of GSK plc (NYSE:GSK – Free Report) during the fourth quarter, ...

J.P. Morgan analyst James Gordon maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.40.

GSK (NYSE:GSK – Get Free Report) was downgraded by investment analysts at StockNews.com from a “strong-buy” rating to a “buy” ...

GSK’s share price has been pressured recently from several negative events, but this may leave a bargain to be had. I've ...

We recently published a list of 12 Undervalued Defensive Stocks for 2025. In this article, we are going to take a look at ...

The FTSE 100 index has started the year well as it surged to a record high. It moved to a high of £8,645, up by over 75% from ...

Jefferies analyst Peter Welford maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.50. The ...

New shares at such a low price could add value to my existing holding in GSK. But I need to check that there is value in the stock. Such a fall could also indicate that the company is simply worth ...

These price increases are likely to affect ... If you are looking for an AI stock that is more promising than GSK but that trades at less than 5 times its earnings, check out our report about ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...